Kaveh Kahen returns to Phenomenex parent Danaher Life Sciences after having begun his career at SCIEX.
Kaveh Kahen, PhD, has been appointed president of Phenomenex, the Torrance, California-based separation science technology company, according to a press release. Kahen succeeds Matt Turner, who moved on from the Phenomenex presidency to pursue other opportunities, the company said.
"I am honored to join a company revered for its innovation, dedication, and excellence in the world of chromatography and analytical sciences,” Kahen said in the release. “As president, I can reaffirm that our focus remains steadfast on delivering groundbreaking solutions and unmatched service to our partners and customers in the life sciences sector."
Phenomenex operates within the Life Sciences group of Danaher Corporation, making this a homecoming of sorts for Kahen. After obtaining his PhD in analytical chemistry from The George Washington University, he began his professional career at SCIEX, another Danaher Life Sciences holding.
Following his tenure at SCIEX, Kahen held various leadership posts at PerkinElmer, according to the release, then most recently served as CEO at Advion Interchim Scientific, during which time he integrated that company’s entities in the U.S. and Europe.
Kahen, Phenomenex said, designed and developed numerous new technologies and instruments early in his career, and later as an executive has gained a reputation for driving above-market growth in the fields of life sciences, analytical testing, and lab equipment.
LC–MS/MS-Based System Used to Profile Ceramide Reactions to Diseases
April 26th 2024Scientists from the University of Córdoba in Córdoba, Spain recently used liquid chromatography–tandem mass spectrometry (LC–MS/MS) to comprehensively profile human ceramides to determine their reactions to diseases.
High-Throughput 4D TIMS Method Accelerates Lipidomics Analysis
April 25th 2024Ultrahigh-pressure liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) had been previously proposed for untargeted lipidomics analysis, but this updated approach was reported by the authors to reduce run time to 4 min.